| Ticker Symbol: | CYTX |
|---|---|
| Exchange: | NASD |
| Contact Info: | 3020 Callan Road San Diego CA 92121 858 458-0900 |
| CEO/President: | Christopher J. Calhoun |
| Industry: | Medical - Biomedical / Standard Industry Code: 3841 |
| Description: | Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company\'s preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient\'s own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients. |
| Shares Outstanding: | 26,100 (000) | Market Value: | 111,370 ($000) |
|---|---|---|---|
| Percentage of Inst.Shareholders: | 26.89% | Number of Inst.Shareholders: | 12.70% |
| Last Quarter Sales: | 1.40 ($Mil.) | Last Quarter Net Income: | -8.41 ($Mil.) |
| Last Quarter EPS: | -0.33 | P/E Ratio: | 0 |
| Most Recent Earnings: | Earnings Per Share: | -1.33 | |
| Most Recent Split: | Annual Dividend Rate: | 0 | |
| Most Recent Dividend: | Annual Dividend Yield: | 0% |

| AMGEN | +14.00 | 58.89 | |
| GILEAD SCIENCES | -0.20 | 45.75 | |
| GENENTECH INC | +16.10 | 87.53 | |
| CELGENE CP | -14.40 | 60.46 | |
| BIOGEN IDEC INC | -16.30 | 50.50 |
